Consequences of Caffeine Intake in Sleep Restricted Teenagers

NCT ID: NCT05790161

Last Updated: 2023-05-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-31

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to systematically investigate two prominent factors in teenagers' daily life: Caffeine and sleep restriction (SR) and their combined influence on sleep, cognition, and behavior in healthy adolescents. The main questions it aims to answer are:

The effects of caffeine under conditions of SR and SE:

* on sleep pressure and sleep continuity.
* on BOLD activity differences in reward related areas during a reward task (monetary incentive delay task) and on reaction times (behavioral aspect) in the same task.
* on BOLD activity differences during a risk taking task (wheel of fortune task) and on risky decision-making (behavioral aspect) in the same task.

Participants will be either in the SR or SE condition (between-subject). The protocol consists of 2x of approximately one week in which a participant will receive caffeine or placebo (within-subject) at the last two evenings.

The experiment consists of an ambulatory and a laboratory phase:

* The ambulatory phase consists of 5 nights, including 3 stabilization nights (8h sleep opportunity) prior to 2 nights consisting of either SR with 6h sleep opportunity or SE with 9.5h sleep opportunity. Participants will wear an actiwatch and fill out sleep diaries during this period.
* The laboratory phase will be the 6th evening, night and morning of the protocol and will be spent in our lab. Participants will do the following:
* treatment (caffeine vs. placebo) intake
* saliva sampling
* drug screening
* cognitive tests, including risk-taking and reward task
* filling in questionnaires (sleep diary, sleep quality, sleepiness, mood, expectancy)
* waking and sleep with EEG

The next day, participants will undergo an fMRI scan, including the following:

* resting-state scan
* structural scan
* arterial spin labeling scan
* reward task scan
* risk-taking task scan

Around the scan, participants will fill out/undergo:

* saliva sampling
* questionnaires (reward task, mood, sleepiness, expectancy)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Caffeine Insufficient Sleep

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Within-Design regarding treatment (caffeine vs. placebo). Between-Design regarding sleep manipulation (sleep restriction vs. sleep manipulation)
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators
doubleblind regarding treatment no blinding regarding sleep manipulation

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sleep Restriction

3 nights with 6h sleep opportunity each.

Group Type EXPERIMENTAL

Caffeine

Intervention Type DRUG

2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)

Sleep Extension

3 nights with 9,5h sleep opportunity each.

Group Type EXPERIMENTAL

Caffeine

Intervention Type DRUG

2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Caffeine

2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 14 and ≤ 17
* Clinically healthy
* Signed consent form of participant and legal guardian

Exclusion Criteria

* Inability to operate tasks or understand the study information
* Participation in other clinical trials \<3 months prior to any possible study start date
* BMI P3 \< BMI-PC \< P97
* Any general health concerns or disorders (previous diagnosis of heart/cardiovascular/nephrological/endocrinological/diabetic/metabolic/chronobiologic/ psychiatric/neurological \[particularly epilepsy and parasomnia\] conditions) which may make participants vulnerable to potential negative effects of SR or caffeine or which may affect outcome measures
* Unavailability to complete the two study protocol weeks within a three-month period
* Trans meridian travel (\>2 time zones) \<1 month before any possible study start date
* Shift work \<3 months prior to any possible study start date
* Extreme chronotype MSFSC \< 3:00 / MSFSC \> 6:00 according to MCTQ
* Subjective sleep duration on school days \<7h or \>9h according to MCTQ
* Metallic prosthesis, metallic implants, or non-removable objects in the body (e.g., splinters, piercings) which affect MRI safety
* Tattoos with larger diameter than 10cm or above shoulder area, affecting MRI safety
* Claustrophobia
* Difficulties or problems in physical well-being and mental health based on the Swiss norm (T\< 35) for all genders aged 12-18 according to KIDSCREEN-27
* Daily nicotine use
* Use of medications or drugs that have contraindications and/or effects on outcome measures or use of specific drugs indicated in drug test
* Use of alcohol to an extent that it is likely to have contraindications and/or effects on outcome measures
* Any indication of previous withdrawal or oversensitivity to caffeine
* Sleep quality \>5 according to PSQI
* Problems of EEG compatibility
* Sleep efficiency \<70%
* Identification of sleep disorders
* Pregnancy
* Deviation from the stabilisation sleep-wake schedule by +-60 mins
* Deviation from protocol sleep-wake schedule by +-30 mins
Minimum Eligible Age

14 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role collaborator

University of Basel

OTHER

Sponsor Role collaborator

University Hospital, Basel, Switzerland

OTHER

Sponsor Role collaborator

University of Pittsburgh

OTHER

Sponsor Role collaborator

University of Liege

OTHER

Sponsor Role collaborator

Psychiatric Hospital of the University of Basel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Carolin Reichert

Deputy Head

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carolin Reichert, Dr.

Role: PRINCIPAL_INVESTIGATOR

University of Basel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre for Chronobiology

Basel, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Carolin Reichert, Dr.

Role: CONTACT

+41 77 488 42 45

Noëmi Capdevila, MSc

Role: CONTACT

+41 79 489 11 64

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Carolin Reichert, Dr.

Role: primary

+ 41 77 488 42 45

Noëmi Capdevila, MSc

Role: backup

+41 79 489 11 64

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CaReTeens

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Caffeine and Resistance Training in Older Adults
NCT06618261 ENROLLING_BY_INVITATION NA
Caffeine and Cerebrovascular Reactivity
NCT04730193 COMPLETED EARLY_PHASE1
Effect of Caffeine on Fetal Growth
NCT00131690 COMPLETED PHASE4
Energy Drinks & Driving Ability
NCT01007877 COMPLETED NA